The latest price target for Conmed (NYSE:CNMD) was reported by Stifel on February 6, 2025. The analyst firm set a price target for $75.00 expecting CNMD to rise to within 12 months (a possible 22.69% upside). 16 analyst firms have reported ratings in the last year.

The latest analyst rating for Conmed (NYSE:CNMD) was provided by Stifel, and Conmed maintained their buy rating.

The last upgrade for Conmed Corp happened on March 27, 2023 when Keybanc raised their price target to $124. Keybanc previously had a sector weight for Conmed Corp.

The last downgrade for Conmed Corp happened on February 6, 2025 when JP Morgan changed their price target from $85 to $70 for Conmed Corp.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Conmed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Conmed was filed on February 6, 2025 so you should expect the next rating to be made available sometime around February 6, 2026.

While ratings are subjective and will change, the latest Conmed (CNMD) rating was a maintained with a price target of $72.00 to $75.00. The current price Conmed (CNMD) is trading at is $61.13, which is out of the analyst’s predicted range.